Pharmaceutical firm Merck and AMCM have declared a partnership through which they will create additively manufactured tablet formulations. AMCM is German custom 3D printing and a sister firm to EOS.
The collaboration focuses on developing a tablet additive manufacturing procedure that adheres to GMP, Good Manufacturing Practice measures for clinical tests and finally for marketing manufacturing services.
Additively manufactured pills are getting friction in healthcare as pharmaceutical and drug firms find out the possibility of 3D printing to customize dosages and medicine. In this situation, Merck anticipates leveraging additive manufacturing to attain huge scalability for active pharmaceutical development formulations by reducing dependence on expensive reformulations around the entire medical development and manufacturing procedure.
The pharma leader sees a chance to utilize additive manufacturing to make pills in a more price and time-efficient way.
“Our partnership with AMCM/EOS has the potential to revolutionize the way tablets are produced. It will be a massive move towards digitalization of the industry,” says Chief Strategy Officer at Merck, Isabel de Paoli.
“Our goal is to develop the industrial application of this technology, which we will make available for clinical trials first, and then move to full digital solutions at commercial scale,” she added.
Through the collaboration, AMCM will supply a personalized powder bed blending procedure that will allegedly ease the clinical advancement of medicines. The additive manufacturing technology is supposed to set the stage for more adaptable and manageable tablet manufacturing. This is by allowing regional production that may address particular market needs and by being flexible to patient requirements.
“We are excited to support Merck on its innovation journey. This cooperation combines Merck’s formulation competences in Healthcare as well as its excipient expertise in Life Science with our long-standing additive manufacturing know-how. Together, we will help make drug development more flexible and faster,” says CEO of EOS, Marie Langer.
The additive manufactured tablet plan will be directed by the Innovation Center at Merck’s headquarters in Darmstadt, Germany.